Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitae Corp.

www.invitae.com

Latest From Invitae Corp.

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

Jones And Luber Partner Up Again At Atlas Genetics

Marc Jones is taking on the dual role of chief operating officer and chief financial officer at UK point-of-care diagnostics firm Atlas Genetics.

Appointments In Vitro Diagnostics

M&A Analysis: M&A Loses Momentum In November

M&A activity tumbled in November after October's big boom. Nine deals were recorded on Medtech Insight's M&A Deal Tracker, repeating the low deal count seen in the same period last year. However, the month saw a handful of notable deals, including Philips' eighth acquisition of the year.

M & A Deals

M&A Analysis: July M&A Levels Reach Fever Pitch

The summer season is proving to be a hot one for medtech M&A activity, with another busy month of deal-making in July. Twenty-five deals were announced and closed during the month, surpassing June's deal count and making it the month with the highest M&A activity to date.

M & A Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Invitae Corp.
  • Senior Management
  • Sean E George, PhD, CEO
    Robert Nussbaum, MD, CMO
  • Contact Info
  • Invitae Corp.
    Phone: (415) 374-7782
    1400 16th St.
    San Francisco, CA 94103
    USA
UsernamePublicRestriction

Register